|Application ||WB, IHC-P, ICC, IP|
|Dilution||IHC-P (5 µg/ml), WB (2 µg/ml),|
|Other Names||Tumor protein p73, p53-like transcription factor, p53-related protein, TP73, P73|
|Target/Specificity||Full-length human p73. It reacts with an epitope that is located on the N-terminal region of human p73. It does not cross react with p53.|
|Reconstitution & Storage||Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles.|
|Precautions||TP73 / p73 Antibody (N-Terminus, clone 5B429) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein.|
|Cellular Location||Nucleus. Cytoplasm. Note=Accumulates in the nucleus in response to DNA damage|
|Tissue Location||Expressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein.
Kaghad M.,et al.Cell 90:809-819(1997).
Mai M.,et al.Genomics 51:359-363(1998).
De Laurenzi V.,et al.J. Exp. Med. 188:1763-1768(1998).
De Laurenzi V.,et al.Cell Death Differ. 6:389-390(1999).
Yoshikawa H.,et al.Oncogene 18:3415-3421(1999).
If you have any additional inquiries please email technical services at email@example.com.